An open-label study of the capacity of MabThera plus first-line treatment with infusional CDE [cyclophosphamide + doxorubicin + etoposide] to induce a clinical response in patients with HIV-related non-Hodgkin's lymphoma.
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Cyclophosphamide; Doxorubicin; Etoposide; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 09 Jun 2006 New trial record.